UCB Group has secured a green light in the EU for the osteoporosis drug Evenity (romosozumab). Winning over the European Medicines Agency’s Committee for Medicinal Products for Human Use after it issued a negative opinion in June is a boon for the Belgian firm, which is responsible for sales in Europe, and its partner Amgen Inc.. However, commercial success is by no means assured.
Evenity Gets CHMP Nod On Second Pass
UCB/Amgen Osteoporosis Drug Will Still Face Market Challenges
UCB and Amgen’s osteoporosis drug Evenity has been given a positive opinion in Europe after initial rejection. But cardiovascular safety concerns and rival products constrain sales potential.
More from New Products
More from Scrip
• By
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.